Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P950037/S291

PSW 2601.U, NEO 2601.U, Amvia Sky HF-T QP, Amvia Sky HF-T, Amvia Edge HF-T QP, Amvia Sky DR-T, Amvia Sky SR-T, Amvia Edg

Biotronik, Inc. · Decision date Sep 17, 2026

MEDTECHLEDGER EXPLANATIONP950037/S291

What did the FDA approve?

On 2026-09-17, FDA recorded an approval decision for P950037/S291, a PMA supplement submitted by Biotronik, Inc. The supplement is classified as a Real-Time Process submission with the stated reason "Change Design/Components/Specifications/Material." The recorded statement describes approval for updated programmer software PSW 2601.U and NEO 2601.U.

The title field lists the software alongside several device names, including Amvia Sky and Amvia Edge pacemaker models; the source does not specify which listed components the change touches. The underlying device category is implantable pacemaker pulse-generator, specialty Cardiovascular, product code DXY. This action covers the supplement's recorded scope only, not a new approval of the whole system. The source provides no documents, so clinical or labeling details of the change remain unknown.

Readers should not infer performance, safety or labeling consequences from the decision code alone; the absence of supporting documents limits interpretation.

FDA approval order statement

approval for updated programmer software PSW 2601.U and NEO 2601.U
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Sep 17, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P950037/S291
Regulatory pathway
PMA supplement
Product code
DXY
Decision code
APPR
Decision date
Sep 17, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: implantable pacemaker Pulse-generator.

Product code
DXY
FDA device class
3

For the original device and its historical approval scope, see PMA P950037. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P950037 · Original PMA

    DROMOS DR/DR-A AND DROMOS SR/SR-B CARDIAC PACING SYSTEMS

  2. P950037/S291 received

    Application receipt date recorded by FDA.

  3. P950037/S291 · FDA decision

    Real-Time Process

  4. P950037/S279 · Related supplement

    Edora 8 DR-T 407145, Evity 8 DR-T 407146, Enitra 8 DR-T 407147, Enticos 8 DR-T 407148, Evity 6 DR-T 407149, Enitra 6 DR-

  5. P950037/S296 · Related supplement

    Edora 8 DR-T 407145; Evity 8 DR-T 407146; Enitra 8 DR-T 407147; Enticos 8 DR-T 407148; Evity 6 DR-T 407149; Enitra 6 DR-

  6. P950037/S298 · Related supplement

    Edora 8 DR-T, Evity 8 DR-T, Enitra 8 DR-T, Evity 6 DR-T, Enitra 6 DR-T, Edora 8 DR, Enitra 6 DR, Enticos 4 DR, Enticos

  7. P950037/S299 · Related supplement

    Edora 8 DR-T, Evity 8 DR-T, Enitra 8 DR-T, Enticos 8 DR-T, Evity 6 DR-T, Enitra 6 DR-T, Edora 8 DR, Enitra 6 DR, Edora 8

  8. P950037/S300 · Related supplement

    Amvia Sky DR-T, Amvia Sky SR-T; Amvia Edge DR-T, Amvia Edge SR-T; Solvia Rise DR-T, Solvia Rise SR-T; Amvia Sky HF-T QP,

Timeline entries are records held by MedtechLedger for P950037. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P950037

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biotronik, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6024 Jean Rd., Lake Oswego, OR, 97035

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records